Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard G Bach

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Pageof 7